Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05845671
Title Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Colorado, Denver
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST